Antibacterial Drug Development-HABP/VABP Studies
CTTI Presents on Cost Drivers of HABP/VABP Phase Three Clinical Trials at ICAAC/ICC 2015
We are pleased to announce that CTTI’s HABP/VABP Trials Project will be presenting a poster at ICAAC/ICC 2015. In September, the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy and Infection (ICC) will host this conference, intended for clinical microbiologists, infectious disease physicians, researchers, and pharmacists.
Session Details:
- Title: Cost Drivers of Hospital Acquired Bacterial Pneumonia and Ventilator Associated Bacterial Pneumonia (HABP/VABP) Phase Three Clinical Trials
- Date: September 18, 2015
- Time: 12:00 – 2:00 PM
- Presenter: Stella Stergiopoulos
We look forward to connecting with colleagues at this event.
ABDD HABP/VABP Pilot Study Workshop
FEBRUARY 24, 2015
CTTI Project: HABP/VABP Studies
Meeting Goal
To determine the study design for the CTTI Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) pilot study. The study will test the principles and recommendations identified in the CTTI Program on Antibacterial Drug Development (ABDD).
Meeting Location:
Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Rd, Bethesda, Maryland 20852
Meeting Presentations:
- Introduction by Pamela Tenaerts, MD, MBA, CTTI
- Project Overview by Rosemary Tiernan, MD, MPH, Office of Medical Policy/CDER/FDA
- CTTI HABP/VABP Pilot Study Preliminary Planning by Sara Bristol Calvert, PharmD, CTTI
- Calculating the Direct and Indirect Costs of a Phase III HABP/VABP Clinical Study by Stella Stergiopoulos, Tufts CSDD
- CTTI HABP/VABP Pilot: Proposed Study Designs by Vance Fowler, MD, MHS, Duke University Medical Center
The views and opinions expressed in this presentation are those of the individual presenter and should not be attributed to the Clinical Trials Transformation Initiative, or any organization with which the presenter is employed or affiliated.